See how top analysts and institutions rate META — including buy, hold, and sell recommendations.
| Rating Source | Action | Rating | Target Price | Updated |
|---|---|---|---|---|
| Oppenheimer | Reiterated | Outperform | $870 → $825 | 2025-10-20 |
| Wells Fargo | Reiterated | Overweight | $811 → $837 | 2025-10-07 |
| Mizuho | Initiated | Outperform | $925 | 2025-09-30 |
| Citizens JMP | Reiterated | Mkt Outperform | $750 → $900 | 2025-07-31 |
| BofA Securities | Reiterated | Buy | $775 → $900 | 2025-07-31 |
| Pivotal Research Group | Reiterated | Buy | $830 → $930 | 2025-07-31 |
| Wedbush | Reiterated | Outperform | $750 → $920 | 2025-07-31 |
| Citigroup | Reiterated | Buy | $803 → $915 | 2025-07-31 |
| KeyBanc Capital Markets | Reiterated | Overweight | $800 → $905 | 2025-07-31 |
| TD Cowen | Reiterated | Buy | $800 → $875 | 2025-07-31 |
| UBS | Reiterated | Buy | $812 → $897 | 2025-07-31 |
| JP Morgan | Reiterated | Overweight | $795 → $875 | 2025-07-31 |
| Morgan Stanley | Reiterated | Overweight | $750 → $850 | 2025-07-31 |
| Monness Crespi & Hardt | Reiterated | Buy | $780 → $860 | 2025-07-31 |
| BMO Capital Markets | Reiterated | Market Perform | $610 → $710 | 2025-07-31 |
| Bernstein | Reiterated | Outperform | $775 → $900 | 2025-07-31 |
| Wells Fargo | Reiterated | Overweight | $783 → $811 | 2025-07-31 |
| Oppenheimer | Reiterated | Outperform | $775 → $870 | 2025-07-31 |
| Guggenheim | Reiterated | Buy | $725 → $800 | 2025-07-28 |
| Canaccord Genuity | Reiterated | Buy | $825 → $850 | 2025-07-16 |
| Needham | Upgrade | Underperform → Hold | 2025-07-03 | |
| UBS | Reiterated | Buy | $683 → $812 | 2025-06-26 |
| Date | Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|---|
| November 2025 | 9 | 49 | 9 | 0 | 1 |
| October 2025 | 9 | 48 | 10 | 0 | 1 |
| September 2025 | 9 | 50 | 8 | 0 | 1 |
| August 2025 | 9 | 50 | 8 | 0 | 1 |
The majority of institutional investors have issued a "Buy" rating for META, and analyst sentiment aligns closely, with very few "Sell" recommendations. This suggests a broadly favorable outlook for the stock's performance.
